華東醫藥(000963.SZ):利拉魯肽糖尿病適應症實現國內首家獲批,其減肥適應症有望於年內獲批,填補國內減重藥物的市場空缺
格隆匯4月18日丨華東醫藥(000963.SZ)於2023年4月14日15:00-16:00召開2022年度業績交流會,內分泌領域,公司首個生物類似藥產品利拉魯肽糖尿病適應症實現國內首家獲批,其減肥適應症有望於年內獲批,填補國內減重藥物的市場空缺。2022年6月,中美華東與中東知名企業JULPHAR就利拉魯肽注射液的雙適應症達成戰略合作,標誌着公司糖尿病領域實力及研發創新能力得到國際認可。圍繞GLP-1靶點,公司自主研發並擁有全球知識產權的糖尿病1類化藥新藥HDM1002 (小分子GLP-1受體激動劑)已完成IND中美雙報,標誌着公司自主研發已經進入一個新階段;控股子公司道爾生物基於其自主研發的Multip le Body®平台技術開發了DR10624,為全球首創(first-in-class)具有三重激動活性,同時靶向GLP-1受體(GLP-1R)、GCG受體(GCGR)和FGFR1c/Klothoβ(FGF21R)的Fc融合蛋白藥物,已於2022年6月順利完成海外臨牀首例入組。此外,公司自主研發的GLP-1R和GIPR長效多肽雙靶點激動劑HDM1005,從立項到獲得PCC分子不到一年,體現了華東創新速度,也標誌着公司自主研發能力的快速提升。目前,圍繞GLP-1靶點,公司已構築了包括口服、注射劑在內的長效及多靶點全球創新藥和生物類似藥相結合的全方位和差異化的產品管線,不斷鞏固公司在內分泌領域的國內領跑者地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.